Skip to main content
Have a personal or library account? Click to login
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice Cover

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Radiology and Oncology
Volume 55 (2021): Issue 4 (December 2021)
By: ,   and    
Open Access
|May 2021
Articles in this issue
DOI: https://doi.org/10.2478/raon-2021-0021 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 491 - 498
Submitted on: Sep 27, 2021
Accepted on: Mar 7, 2021
Published on: May 4, 2021
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
PD-L1 inhibitor,
urothelial cancer,
bladder,
atezolizumab,
overall survival,
immune checkpoint inhibitor,
prognostic factors
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2021 Marina Mencinger, Dusan Mangaroski, Urska Bokal, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 55 (2021): Issue 4 (December 2021)
Previous article
Next article